Philadelphia, PA – According to filings with the U.S. Securities and Exchange Commission, Imvax is raising $112,370,500.00 in new funding. Sources indicate as part of senior management Chief Business Officer, Arthur Howe played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Imvax

Imvax is a clinical-stage biotechnology company with a unique immunotherapy approach to solid tumors. Imvax was founded by a neurosurgeon striving to change the landscape of treatment for GBM patients to extend both the duration and quality of their lives. Our mission is to reimagine the standard of care for solid tumors through personalized immunotherapy.

To learn more about Imvax, visit http://www.imvax.com/

Contact:
Arthur Howe, Chief Business Officer
215-485-0071
https://www.linkedin.com/in/arthowe/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved